Reid Hoffman's exit from Microsoft's board closes a long chapter in one of tech's most influential relationships. Hoffman joined after Microsoft acquired LinkedIn and remained a central figure as the company repositioned itself around cloud, AI, and OpenAI. Now he is leaving governance work to focus more directly on Manus, his AI drug-discovery startup.
The move reflects a broader pattern among veteran tech investors and operators. The most ambitious AI opportunities increasingly sit outside advisory roles and board seats. They require founders to recruit teams, shape product strategy, secure compute, and work closely with domain experts. In biotech, that also means navigating scientific validation and regulatory pathways.
Manus is part of a growing wave of companies applying AI to drug discovery, target identification, trial design, and molecular search. The category has produced excitement and disappointment in equal measure because biological complexity resists simple software metaphors. Hoffman's decision suggests he sees enough progress to justify more direct involvement.
For Microsoft, the departure does not signal distance from AI. The company remains deeply committed to the sector. But it does mark a generational handoff: one of the architects of the social web is choosing to spend more time building in the next frontier rather than overseeing the last one.
Source context: TechCrunch
